• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How to Choose an Antipsychotic in Schizophrenia

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020
Rehan Aziz, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It’s been over a decade since the CATIE trial changed the way we look at antipsychotic drugs. Since then, the number of second-generation antipsychotics has about doubled, and the number of clinical trials has risen even more. Antipsychotics are not all the same, though, and when it comes to schizophrenia, a few stand out in ways that can help you fine-tune your selection. In this article, we’ll look back at the past decade and highlight findings that could change clinical practice, while drawing from some new meta-analyses.


The CATIE trial
CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) was a double-blind, NIMH-sponsored study. It involved almost 1500 patients with chronic schizophrenia studied under “real-world” conditions. Patients were initially randomized to receive olanzapine, quetiapine, risperidone, or ziprasidone. Later stages included open-label clozapine. The goal was to measure the effectiveness of second-generation antipsychotics vs each other and against a first-generation antipsychotic, perphenazine.


When the dust settled, olanzapine came out on top, at least when patients voted with their feet. Patients stayed on olanzapine longer than any other antipsychotic, suggesting its benefits outweighed its side effects. Those side effects were significant, though, as olanzapine had the highest rate of weight gain and metabolic problems. In the later stages of the study, clozapine was the champ—patients stayed on it twice as long as on olanzapine. Perhaps the most stunning finding was that despite all their fanfare, second-generation antipsychotics were no more efficacious or better tolerated than perphenazine (Lieberman JA and Stroup TS, Am J Psychiatry 2011;168(8):770–775).


New findings
Although the CATIE trial suggests olanzapine should be the first choice for schizophrenia, it’s often reserved as a second-line option because of its metabolic risks. Where, then, to start? The Harvard South Shore Psychopharmacology Algorithm Project (www.psychopharm.mobi) combines real-world scenarios with randomized controlled trials to help answer these kinds of questions. Medications in the project’s flowcharts are chosen for their balance of efficacy, side effects, and cost. The project lists first-line treatments for schizophrenia as aripiprazole, risperidone, or ziprasidone. If cost is not an issue, cariprazine could be added to this list, since there is some evidence it improves negative symptoms. Second-line options include an alternate second-generation antipsychotic, risperidone if not already tried, olanzapine, or a first-generation antipsychotic. Clozapine is reserved for treatment-resistant cases, defined as failure to respond to 2 or more antipsychotics (Osser DN et al, Harv Rev Psychiatry 2013;21(1):18–40).


Negative symptoms of schizophrenia have eluded treatment for decades. A meta-analysis looked at 168 trials involving more than 12,000 patients. Researchers found that many treatments reduced negative symptoms, including second-generation antipsychotics, antidepressants, and psychological interventions, but none resulted in clinically significant improvement (Fusar-Poli P et al, Schizophr Bull 2015;41(4):892–899). Cariprazine may offer some hope. In a single study, cariprazine decreased negative symptoms more than risperidone, though the effect size (0.31) was small (Nemeth G et al, Lancet 2017;389(10074):1103–1113). Risperidone also lost out to aripiprazole in a separate study, though aripiprazole-treated patients had more akathisia (Robinson DG et al, Schizophr Bull 2015;41(6):1227–1236).


Overall, the choice of a first antipsychotic is often based on side effects instead of efficacy. The table below may help guide your decision making.



Table: Side Effects of Atypical Antipsychotics


Table: Side Effects of Atypical Antipsychotics


(Click to view as full-size PDF)



Treatment-resistant schizophrenia
Clozapine is still the gold standard in treatment-resistant cases, but it needs to be started early. The likelihood of responding to clozapine drops by 8%–11% with every failed antipsychotic trial, and the chance of clozapine working goes down from 82% to 32% if it is started longer than 3 years after a first episode (John AP et al, Can J Psychiatry 2018;63(8):526–531; Yoshimura B et al, Psych Res 2017;250:65–70). Clozapine should be considered after failure of 2 antipsychotic trials, with failure meaning a lack of response—in contrast, treatment resistance in mood disorders is defined by lack of recovery. We don’t expect full recovery right now in schizophrenia, though about 1 in 8 patients do come close and regain their functioning (Charlson FJ et al, Schizophr Bull 2018;44(6):1195–1203).


The US trails other nations in clozapine utilization, likely because of its risks. It’s hard to feel good about starting a medication that can cause neutropenia, seizures, cardiotoxicity, and small bowel obstruction. Those risks must be balanced with the surprising fact that patients who take clozapine actually live longer than those taking other antipsychotics. In a meta-analysis of 24 studies covering over 200,000 life years, the mortality rate was 44% lower with clozapine than other antipsychotics, and that protective benefit disappeared soon after clozapine was discontinued (Vermeulen JM et al, Schizophr Bull 2019;45(2):315–329). A useful guide to managing clozapine’s side effects is Jonathan Meyers’ The Clozapine Handbook (2019).


TCPR Verdict: It could be argued that all of the second-generation antipsychotics outside of clozapine are equal, but we’ll venture a recommendation. Start with aripiprazole or, if cost is not an issue, cariprazine. These stand out for their mild benefits in negative symptoms and favorable long-term side effect profiles. Olanzapine is a good second-line choice when efficacy is more of a consideration. After failure of 2 trials, move quickly to clozapine. See the “Antipsychotic Selection in Schizophrenia” table at left for more.



Table: Antipsychotic Selection in Schizophrenia


Table: Antipsychotic Selection in Schizophrenia


(Click to view as full-size PDF.)


General Psychiatry
KEYWORDS antipsychotics aripiprazole cariprazine clozapine negative-symptoms olanzapine psychopharmacology psychopharmacology_tips psychosis risperidone schizophrenia
Rehan Aziz, MD.

How to Treat and Assess Delirium in Older Patients

More from this author
www.thecarlatreport.com
Issue Date: March 30, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Psychopharmacology Algorithms, TCPR, April 2020
How to Choose an Antipsychotic in Schizophrenia
The Psychopharmacology Algorithm Project
Nuplazid: Novel Mechanism, Modest Benefits
Antipsychotics Fall Short in Delirium
Singulair and Suicide: FDA Strengthens Warning
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto84222831.jpg
    General Psychiatry

    The Adderall Shortage

    Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.